<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.4//EN" "ep-patent-document-v1-4.dtd"><ep-patent-document id="EP0856000A1" file="EP96932841NWA1.xml" lang="en" doc-number="0856000" date-publ="19980805" kind="A1" country="EP" status="n" dtd-version="ep-patent-document-v1-4"><SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSE..PTIE......FI..........................................................</B001EP><B003EP>*</B003EP><B007EP>EPregister to ST.36 EBD process v 1.0 kbaumeister@epo.org (15 Jan 2013)</B007EP></eptags></B000><B100><B110>0856000</B110><B130>A1</B130><B140><date>19980805</date></B140><B190>EP</B190></B100><B200><B210>96932841.0</B210><B220><date>19961008</date></B220><B240><B241><date>19980326</date></B241></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>19950020584</B310><B320><date>19951009</date></B320><B330><ctry>GB</ctry></B330></B300><B400><B405><date>19980805</date><bnum>199832</bnum></B405><B430><date>19980805</date><bnum>199832</bnum></B430></B400><B500><B510EP><classification-ipcr sequence="1"><text>A61K  31/    00            A I                    </text></classification-ipcr><classification-ipcr sequence="2"><text>A61K  31/   415            A I                    </text></classification-ipcr><classification-ipcr sequence="3"><text>A61P  29/    00            A I                    </text></classification-ipcr><classification-ipcr sequence="4"><text>C07D 231/    12            A I                    </text></classification-ipcr><classification-ipcr sequence="5"><text>C07D 231/    14            A I                    </text></classification-ipcr><classification-ipcr sequence="6"><text>C07D 231/    16            A I                    </text></classification-ipcr></B510EP><B540><B541>en</B541><B542>1,3,5-TRISUBSTITUTED PYRAZOLES FOR TREAMENT OF INFLAMMATION</B542><B541>fr</B541><B542>PYRAZOLES 1,3,5-TRISUBSTITUES POUR LE TRAITEMENT DES INFLAMMATIONS</B542><B541>de</B541><B542>1,3,5-TRISUBSTITUIERTE PYRAZOLE ZUR BEHANDLUNG VON ENTZÜNDUNGEN</B542></B540></B500><B700><B710><B711><snm>FUJISAWA PHARMACEUTICAL CO., LTD.</snm><adr><str>4-7, Doshomachi 3-chome Chuo-ku</str><city>Osaka-shi Osaka 541</city><ctry>JP</ctry></adr></B711></B710><B720><B721><snm>MATSUO, Masaaki</snm><adr><str>4-12, Nakasakurazuka 5-chome Toyonaka-shi</str><city>Osaka 560</city><ctry>JP</ctry></adr></B721><B721><snm>OKUMURA, Kazuo</snm><adr><str>3-1, Shinkofudai 1-chome Toyono-cho Toyono-gun</str><city>Osaka 563-01</city><ctry>JP</ctry></adr></B721><B721><snm>OGINO, Takashi</snm><adr><str>41-34, Hiedacho Yamatokooriyama-shi</str><city>Nara 639-11</city><ctry>JP</ctry></adr></B721><B721><snm>NAKAMURA, Katsuya</snm><adr><str>12-1-103, Kamihamuro 2-chome Takatsuki-shi</str><city>Osaka 569</city><ctry>JP</ctry></adr></B721><B721><snm>NISHIMURA, Hiroaki</snm><adr><str>1-2-12-1113, Kimikage-cho Kita-ku Kobe-shi</str><city>Hyogo 651-11</city><ctry>JP</ctry></adr></B721><B721><snm>HARADA, Keiko</snm><adr><str>1-2-10, Nakasujiyamate Takarazuka-shi</str><city>Hyogo 665</city><ctry>JP</ctry></adr></B721><B721><snm>HOTTA, Yuka</snm><adr><str>21-14, Mefu 1-chome Takarazuka-shi</str><city>Hyogo 665</city><ctry>JP</ctry></adr></B721><B721><snm>TSUJI, Kiyoshi</snm><adr><str>170, Hatacho Kishiwada-shi</str><city>Osaka 596</city><ctry>JP</ctry></adr></B721></B720><B740><B741><snm>Türk, Gille, Hrabal, Leifert</snm><adr><str>Brucknerstrasse 20</str><city>40593 Düsseldorf</city><ctry>DE</ctry></adr></B741></B740></B700><B800><B840><ctry>AT</ctry><ctry>BE</ctry><ctry>CH</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>IE</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LU</ctry><ctry>NL</ctry><ctry>PT</ctry><ctry>SE</ctry></B840><B860><B861><dnum><anum>JP1996002919</anum></dnum><date>19961008</date></B861><B862>en</B862></B860><B870><B871><dnum><pnum>WO1997013755</pnum></dnum><date>19970417</date><bnum>199717</bnum></B871></B870></B800></SDOBI></ep-patent-document>